肺癌精准治疗新阶段！强生锐珂捷带来给药最便捷、时间最短一线联合治疗选择

上观新闻09-17 15:06

强生公司日前举办锐珂捷——埃万妥单抗注射液（皮下注射）上市新闻发布会。目前，锐珂捷已获批联合利珂（兰泽替尼），用于经检测确认携带表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）患者的一线治疗。　　锐珂捷是中国首个且目前唯一获批用于治疗EGFR突变晚期NSCLC患者的皮下注射制剂，联合利珂在一线联合治疗中展现出显著的给药便捷性。该方案将给药时间从传统静脉输注的数小时缩短至数分钟，并...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2668954182?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-17 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668954182","market":"sh","top_or_hot":-1,"title":"肺癌精准治疗新阶段！强生锐珂捷带来给药最便捷、时间最短一线联合治疗选择","media":"上观新闻","content":"<div>\n<p>强生公司日前举办锐珂捷——埃万妥单抗注射液（皮下注射）上市新闻发布会。目前，锐珂捷已获批联合利珂（兰泽替尼），用于经检测确认携带表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）患者的一线治疗。　　锐珂捷是中国首个且目前唯一获批用于治疗EGFR突变晚期NSCLC患者的皮下注射制剂，联合利珂在一线联合治疗中展现出显著的给药便捷性。该方案将给药时间从传统静脉输注的数小时缩短至数分钟，并...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609173877268321.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>肺癌精准治疗新阶段！强生锐珂捷带来给药最便捷、时间最短一线联合治疗选择</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n肺癌精准治疗新阶段！强生锐珂捷带来给药最便捷、时间最短一线联合治疗选择\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-17 15:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202609173877268321.html><strong>上观新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>强生公司日前举办锐珂捷——埃万妥单抗注射液（皮下注射）上市新闻发布会。目前，锐珂捷已获批联合利珂（兰泽替尼），用于经检测确认携带表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）患者的一线治疗。　　锐珂捷是中国首个且目前唯一获批用于治疗EGFR突变晚期NSCLC患者的皮下注射制剂，联合利珂在一线联合治疗中展现出显著的给药便捷性。该方案将给药时间从传统静脉输注的数小时缩短至数分钟，并...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609173877268321.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0210528500.USD","symbol_name":"JPM AMERICA EQUITY \"A\" ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609173877268321.html","article_id":"2668954182","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609173877268321.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2668954182","pubTimestamp":1789628797,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"强生公司日前举办锐珂捷——埃万妥单抗注射液（皮下注射）上市新闻发布会。目前，锐珂捷已获批联合利珂（兰泽替尼），用于经检测确认携带表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）患者的一线治疗。锐珂捷是中国首个且目前唯一获批用于治疗EGFR突变晚期NSCLC患者的皮下注射制剂，联合利珂在一线联合治疗中展现出显著的给药便捷性。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0210528500.USD":"JPM AMERICA EQUITY \"A\" ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","TRUH":"VanEck Healthcare TruSector ETF","JNJ":"强生","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","FHLC":"Fidelity MSCI Health Care Index","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1043141396.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) ACC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","PJP":"INVESCO PHARMACEUTICALS ETF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","RXL":"ProShares Ultra Health Care","IXJ":"全球医疗业ETF-iShares","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","XLV":"健康照护类股ETF-SPDR","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","GDOC":"Goldman Sachs Future Health Care Equity ETF","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BMED":"iShares Health Innovation Active ETF","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","VHT":"Vanguard Health Care ETF","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","IYH":"iShares U.S. Healthcare ETF","IHE":"iShares U.S. Pharmaceuticals ETF","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"A new stage of precision treatment for lung cancer! Johnson & Johnson Record brings the most convenient and shortest first-line combination treatment option","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IYH":0.6,"TRUH":0.6,"BMED":0.6,"IHE":0.6,"JNJ":1.5,"VHT":0.6,"XLV":0.6,"GDOC":0.6,"FHLC":0.6,"MEDX":0.6,"JDOC":0.6,"FTXH":0.6,"RXL":0.6,"IXJ":0.6,"PJP":0.6},"content_text":"强生公司日前举办锐珂捷——埃万妥单抗注射液（皮下注射）上市新闻发布会。目前，锐珂捷已获批联合利珂（兰泽替尼），用于经检测确认携带表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）患者的一线治疗。　　锐珂捷是中国首个且目前唯一获批用于治疗EGFR突变晚期NSCLC患者的皮下注射制剂，联合利珂在一线联合治疗中展现出显著的给药便捷性。该方案将给药时间从传统静脉输注的数小时缩短至数分钟，并显著降低输液相关反应风险，标志着肺癌精准治疗迈入全新阶段。　　当前，肺癌治疗理念已从过去单纯追求生存期的延长，逐步转向兼顾治疗疗效、患者全病程生活质量和治疗体验的综合性管理模式。在埃万妥单抗联合兰泽替尼方案所展现出的持久生存获益基础上，锐珂捷提供了一种更为便捷的给药方式，进一步优化了患者的治疗体验。锐珂捷的上市，是JNJ\" target=\"_blank\" web=\"1\">强生以科学创新为基础，践行对中国患者长期承诺的又一重要体现。　　中国工程院院士、山东省肿瘤医院院长于金明教授表示：“在健康中国2030战略引领下，肿瘤慢病化管理已成为提升国民健康水平的关键内容。肺癌在全球发病率和死亡率中均占主要比重，防治压力依然巨大。但令人欣喜的是，随着医学技术不断突破、药物创新持续涌现，越来越多肿瘤患者正在从中获得生存获益。”　　上海东方医院肿瘤科主任、同济大学医学院肿瘤研究所所长周彩存教授表示：“过去二十年，EGFR突变非小细胞肺癌领域见证了精准医学最深刻的变革之一。一至三代EGFR-TKI陆续问世，延长了患者生存，但肺癌尚未被治愈，临床亟需更优的治疗方案，助力更多患者实现长期生存，并推动肺癌迈向慢病管理。埃万妥单抗在该领域发挥了关键作用，尤其在EGFR 20号外显子插入突变这一临床难治人群中带来了生存突破，令人振奋。期待未来能有更多创新药物惠及患者，将科学创新真正转化为患者的生存获益，加快肺癌慢病化步伐。”　　四川大学华西医院肿瘤中心副主任王永生教授表示：“埃万妥单抗作为双特异性抗体，突破了传统小分子靶向药物的平台局限，开辟了全新治疗路径。依托剂型革新，皮下制剂在保持疗效稳定的前提下降低了安全性风险，给药时长由5小时缩短至5分钟，极大提升诊疗便捷度与患者体验，与国内肿瘤日间门诊的建设方向相契合。该创新方案兼顾患者就医便利与医院运营管理，有望进一步夯实长期治疗获益。”　　《中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2026》已将锐珂捷联合兰泽替尼一线治疗EGFR突变晚期NSCLC纳入推荐方案。该指南更新进一步验证了该方案的临床价值，也为我国临床实践提供了有力的循证依据。　　强生创新制药中国区总裁黄琛表示：“在强生，我们的目标不仅在于药物研发创新，更在于确保每一项创新都能为患者带来切实获益。锐珂捷的上市，是扩大中国肺癌患者治疗选择的重要里程碑。展望未来，我们将继续联合医疗专业人士、患者组织及社会各界合作伙伴，持续深化‘以患者为中心’的服务体系建设，提升治疗可及性，推动医患共同决策理念落地，让更多中国患者从医学创新中真正获益。”　　强生还同步启动了“肺癌医患共决策主题论坛”，汇聚临床专家、患者组织及关键利益相关方，共同探讨将医患共决策理念系统融入肺癌全程管理的实践路径。　　现场，多位专家围绕“NSCLC精准治疗新选择的临床价值与患者体验”展开圆桌讨论，分别从体系价值、临床价值、患者价值与未来价值四大维度分享观点。专家指出，肺癌精准治疗的创新不止于疗效突破，剂型革新正在重塑诊疗模式。尤其在慢病化管理趋势下，诊疗理念正由单纯追求生存延长，转向兼顾疗效、安全性、治疗便捷度与患者生活质量。基于这一转变，与会专家进一步强调，未来应持续推进医患共同决策落地，建立多维度创新价值评价体系，并依托数字化手段完善全病程管理，引导患者主动参与治疗决策，从而让药物创新真正转化为可及、可持续的长期获益。　　社会多方力量也展开了深入讨论，认为当前医患共同决策仍面临患者疾病认知不足、就医沟通畏难，以及医疗资源紧张、区域诊疗水平不均、专业决策工具缺失、沟通体系不完善等现实挑战。与会嘉宾认为，患者有效参与决策需以充足认知、清晰表达和完整反馈为前提，而分层化、差异化的患者教育是破解认知壁垒、提升沟通效率的关键。强生通过落地“三思而择”计划、上线国内肺癌医患共决策线上专区、推出决策辅助工具与问题清单生成器等本土化举措，联动多方力量搭建全域患者服务生态，赋能患者主动参与诊疗决策，推动医患共同决策从理念走向实践。　　医患共同决策的核心，不在于单向信息告知，而在于让患者诉求被倾听、被尊重。未来，唯有依托临床实践优化、系统化患者教育、平台工具赋能与行业多方协同，持续推动医患共同决策常态化落地，才能让精准医疗真正适配患者个体化需求，助力患者实现更长生存、更高质量的生活获益。（文章来源：上观新闻）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2668954182","isCrawlerRequest":true}